Document is current
Any future updates will be listed below
-
Authors
Tian, Jihua
Luo, Jing
Zeng, Xing
Ke, Chunjin
Wang, Yanan
Liu, Zhenghao
Li, Le
Zhang, Yangjun
Hu, Zhiquan
Yang, Chunguang https://orcid.org/0000-0002-3882-4940
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01358721 at ClinicalTrials.govnct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
nct01358721 at ClinicalTrials.govDocuments that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
Documents that mention this clinical trial
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2019-000228
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
https://doi.org/10.1136/jitc-2020-001506
189 Systematic evaluation of transcriptomic molecular features in advanced renal clear cell carcinoma treated with immunotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0189
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
https://doi.org/10.1136/jitc-2023-008226
Soluble PD-L1 as an early marker of progressive disease on nivolumab
https://doi.org/10.1136/jitc-2021-003527
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81702989)
- License Information
